“Raleigh, N.C. – August 18, 2015 – Sprout Pharmaceuticals, Inc. (Sprout) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of Addyi™ (flibanserin 100 mg) (pronounced add-ee), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the United States.1″
“Most Common Adverse Reactions
The most common adverse reactions among patients treated with Addyi were dizziness (Addyi 11.4%; Placebo 2.2%), somnolence (Addyi 11.2%; Placebo 2.9%), nausea (Addyi 10.4%; Placebo 3.9%), fatigue (Addyi 9.2%; Placebo 5.5%), insomnia (Addyi 4.9%; Placebo 2.8%) and dry mouth (Addyi 2.4%; Placebo 1.0%).”
..
http://www.sproutpharma.com/sprout-pharmaceuticals-receives-fda-approval-addyi-flibanserin-100-mg/
https://en.wikipedia.org/wiki/Flibanserin
…
“Según documentos publicados en el sitio de la FDA, las mujeres que habían tomado Flibanserina, del grupo Sprout Pharmaceuticals, tuvieron 4,4 experiencias sexuales satisfactorias en un mes, ante las 3,7 en el grupo con efecto placebo y 3,7 antes del inicio del estudio.”
http://elpais.com/elpais/2015/08/19/ciencia/1439944664_755542.html
http://www.elpais.com.co/elpais/salud/noticias/aclare-sus-dudas-sobre-flibanserin-primer-viagra-femenino-eeuu
.
.
